Dermatology practical & conceptual最新文献

{"title":"Clinical and Ultrasonographic Assessment of Nail Psoriasis: A Comprehensive Study.","authors":"Maria Esposito, Lina Maria Magnanimi, Paolo Antonetti, Andrea De Berardinis, Cristina Pellegrini, Emanuele Vagnozzi, Manfredo Bruni, Camilla Gianneramo, Paola Cipriani, Maria Concetta Fargnoli, Antonio Barile, Piero Ruscitti","doi":"10.5826/dpc.1503a5318","DOIUrl":"10.5826/dpc.1503a5318","url":null,"abstract":"<p><strong>Introduction: </strong>In patients with plaque type psoriasis (PsO), the progression to psoriatic arthritis (PsA) exacerbates the disease's impact and increases disability risk. Nail psoriasis (NP) affects up to 90% of PsO patients, with a wide spectrum of clinical features, and is a significant predictor of enthesitis, often associated with early PsA stages.</p><p><strong>Objective: </strong>This study aimed to clinically and ultrasonographically evaluate nail units in PsO patients, focusing on differences between those with/without PsA and those with/without onychopathy.</p><p><strong>Methods: </strong>Sixty patients were enrolled (23/60 PsO and 37/60 PsO and PsA). PsO and PsA patients were evaluated and compared, as were patients with/without diagnosis of nail psoriasis in this cross-sectional single-center study. Nail abnormalities were evaluated by high frequency ultrasound (HFUS) using high frequency probes (27 MHz). After a descriptive assessment, the Nail Psoriasis Severity Index (NAPSI) and the Brown University Nail Enthesis Scale (BUNES) were used to clinically and ultrasonographically assess nails.</p><p><strong>Results: </strong>HFUS evaluation identified a spectrum of nail and blood flow alterations. Nail disease was characterized by median NAPSI 16 (range 28), median BUNES morphometry 1.5 (range 0.9), and median BUNES power doppler (PD) 2.2 (range 4.03). Among the studied sample, 43/60 (71.7%) presented nail psoriasis, with 69.7% presenting coexisting PsA as compared to PsO patients (30.3%) (P=0.04).</p><p><strong>Conclusion: </strong>Our findings highlight the importance of close collaboration between dermatologists and rheumatologists in the evaluation of PsO patients, taking advantage of both clinical and ultrasonographic assessment of nail damage.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 3","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Study of CO₂ Laser and Curettage-Electrodesiccation for Superficial Basal Cell Carcinoma Treatment: A Focus on Cosmetic Results.","authors":"Pelle Kahr Nilsson, Ulrik Knap, Rasa Laurinaviciene, Sebastian Vigand Svendsen, Tine Vestergaard","doi":"10.5826/dpc.1503a5368","DOIUrl":"10.5826/dpc.1503a5368","url":null,"abstract":"<p><strong>Introduction: </strong>Basal cell carcinoma (BCC) is the most common type of skin cancer worldwide, and the incidence is rising. While surgical excision remains the gold standard, it can be time-consuming and resource-intensive. Therefore, there is a growing need for simpler and more cost-effective treatment options for low-risk tumors.</p><p><strong>Objectives: </strong>This study compared the scar quality and the recurrence rate from continuous wave CO₂ laser and curettage and electrodesiccation treatments. Scar quality and the recurrence rate from the treatments were assessed.</p><p><strong>Methods: </strong>A single-blind randomized prospective interventional trial was conducted at Odense University Hospital, Denmark, from 2017 to 2023. Patients with histologically confirmed superficial BCC were randomized 1:1 to Curettage-Electrodesiccation (CE) or continuous wave CO₂ (CW CO₂) laser treatment. Scar quality was assessed using the Patient and Observer Scar Assessment Scale (POSAS) and a modified visual-only scale (VSAS). Recurrence within one year was a secondary outcome.</p><p><strong>Results: </strong>Thirty-two patients were treated for 32 tumors: 17 with CE and 15 with CO₂ laser. There was no significant difference in scar quality or recurrence rate between the CE and CO₂ laser groups (PSAS: P = 0.422; OSAS: P = 0.747; VSAS: P = 0.522). After one year, neither group showed tumor recurrence.</p><p><strong>Conclusion: </strong>CO₂ laser used in continuous wave setting offers a treatment for superficial BCCs with cosmetic outcomes and recurrence rates comparable to CE. However, a larger patient sample and longer follow-up are needed for definitive conclusions.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 3","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reactive Infectious Mucocutaneous Eruption (RIME): Narrative Review and Proposed Management Algorithm.","authors":"Víctor García-Rodríguez, Maribel Iglesias-Sancho, Albert Martin-Poch, Maria Teresa Fernández-Figueras, Montserrat Salleras-Redonnet","doi":"10.5826/dpc.1503a5083","DOIUrl":"10.5826/dpc.1503a5083","url":null,"abstract":"<p><strong>Introduction: </strong>RIME is an emerging dermatologic condition marked by prominent mucositis with minimal skin involvement, often mimicking Stevens-Johnson syndrome. While initially linked to Mycoplasma pneumoniae, a broader range of infectious triggers is now recognized.</p><p><strong>Objectives: </strong>We present a narrative review of this entity. A proposed diagnostic and therapeutic algorithm is also provided to aid clinicians in clinical practice.</p><p><strong>Methods: </strong>We performed a narrative review of English-language literature on RIME and MIRM indexed in PubMed through 2024, supplemented by clinical insights from the experience of our centre.</p><p><strong>Results: </strong>Evidence regarding treatment is lacking, with systemic steroids and/or cyclosporine A showing the most benefit. RIME usually portends a good prognosis, with recovery within seven to 21 days, although complications can occur. Recurrences are rare, and subsequent episodes can be triggered by different microorganisms.</p><p><strong>Conclusions: </strong>RIME represents a distinct clinical entity with a broadening range of infectious triggers beyond Mycoplasma pneumoniae. Prompt recognition, accurate differentiation from mimickers, and a structured diagnostic and therapeutic approach are essential for effective management and improved patient outcomes.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 3","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Disease Activity-Guided Dose Reduction on IL-17 and IL-23 Inhibitors in Psoriasis: A Real-World Assessment of Efficacy, Safety, and Economic Benefits.","authors":"Edoardo Cammarata, Chiara Airoldi, Jacopo Colombo, Andrealuna Ucciero, Luca Mastorino, Veronica Arese, Lorenza Burzi, Franco Castelli, Massimo Chiarpenello, Francesca Graziola, Claudia Leporati, Michela Ortoncelli, Paolo Pella, Ginevra Pertusi, Alessia Pisterna, Pietro Quaglino, Simone Ribero, Gianluca Rossotto, Rossana Tiberio, Paolo Dapavo, Paola Savoia","doi":"10.5826/dpc.1503a5845","DOIUrl":"10.5826/dpc.1503a5845","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis is a chronic inflammatory multisystem disease for which IL-17 and IL-23 inhibitors have transformed treatment. However, high costs and the possibility of overtreatment in patients with excellent and sustained responses have driven interest in dose reduction (DR) to lower expenses without compromising efficacy.</p><p><strong>Materials & methods: </strong>We conducted a multicenter observational trial assessing the efficacy and safety of DRs for secukinumab, brodalumab, guselkumab, and risankizumab in adults with stable plaque psoriasis. Eligible participants were adults with low disease activity (PASI ≤ 3, DLQI ≤ 3 for at least 9 months). DR involved lengthening intervals to approximately 67% of the authorized standard dose. From the 361 enrolled (March 2023-January 2025), we analyzed data on 156 participants with ≥12 months of follow-up or early discontinuation due to DR failure.</p><p><strong>Results: </strong>Seventy of these patients (44.87%) received IL-17 inhibitors, and 86 (55.13%) received IL-23 inhibitors. After 52 weeks, the overall dose-reduction survival was 0.75 (95% CI: 0.69-0.82). For IL-23 inhibitor and IL-17 inhibitor cohorts, the dose-reduction survival was 0.83 (95% CI: 0.75-0.91) and 0.66 (95% CI: 0.55-0.78), respectively. Moreover, Kaplan-Meier curves suggested significant (p-value log-rank test=0.018) higher dose reduction survival for IL-23 inhibitors compared to IL-17.</p><p><strong>Discussion: </strong>Our preliminary findings suggest that extended dosing intervals for IL-17 and IL-23 inhibitors can effectively maintain disease control in stable plaque psoriasis. Larger randomized trials are needed to confirm these results, identify predictive markers of DR success, and optimize patient selection for safe and cost-effective management of psoriasis.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 3","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Satisfaction with Calcipotriol/Betamethasone Dipropionate Cream in Psoriatic Patients Previously Treated With Foam Vehicle.","authors":"Giacomo Caldarola, Enrico Bocchino, Eleonora De Luca, Alessandra D'Amore, Niccolò Gori, Clara De Simone, Ketty Peris","doi":"10.5826/dpc.1503a5696","DOIUrl":"10.5826/dpc.1503a5696","url":null,"abstract":"<p><strong>Introduction: </strong>Topical therapy is the first-line treatment for mild-to-moderate psoriasis, and guidelines recommend the combination of calcipotriene and betamethasone dipropionate (Cal/BD) as the preferred option, with its wide range of available formulations.</p><p><strong>Objectives: </strong>The aims of this study were to assess the preference for Cal/BD cream in a group of patients previously treated with Cal/BD foam spray and to evaluate their satisfaction with the treatment.</p><p><strong>Method: </strong>We conducted a prospective observational study on psoriatic patients treated with Cal/BD cream who had used Cal/BD foam in the previous three months. After four weeks of treatment, the comparison between the cream and the previous treatment with the foam was evaluated by a Patient Preference Questionnaire (PPQ). Additionally, patient satisfaction was evaluated through Psoriasis Treatment Convenience Scale (PTCS) and the Topical Therapy Adherence Questionnaire (TTAQ).</p><p><strong>Results: </strong>Thirty patients with mild-to-moderate psoriasis were enrolled. After 28 days of treatment, PASI, BSA, and DLQI scores showed significant improvement (P<0.03). According to the Patient Preference Questionnaire (PPQ), 24/30 patients found Cal/BD cream overall preferable to the Cal/BD foam formulation. Moreover, PTCS and TTAQ questionnaires found a very high level of satisfaction with the cream.</p><p><strong>Conclusion: </strong>These findings suggest that Cal/BD cream represents a valuable therapeutic option for patients starting topical treatment thanks to its high cosmetic acceptability.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 3","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three Novel Mutations in ALOX12B Gene in Patients with Autosomal Recessive Congenital Ichthyosis from Turkey.","authors":"Özge Zorlu, Semih Aşıkovalı","doi":"10.5826/dpc.1503a5331","DOIUrl":"10.5826/dpc.1503a5331","url":null,"abstract":"","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 3","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and Histopathological Insights into Acantholytic Dyskeratotic Acanthoma: A Case Series.","authors":"Buğra Burç Dağtaş, Cem Leblebici, Cemre Büşra Türk, Asude Kara Polat, Ayşe Esra Koku Aksu","doi":"10.5826/dpc.1503a5455","DOIUrl":"10.5826/dpc.1503a5455","url":null,"abstract":"","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 3","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Efficacy of Tirbanibulin in Actinic Keratosis Treatment: Expert Consensus and Clinical Insights.","authors":"Marco Ardigò, Giuseppe Argenziano, Elena Campione, Stefania Guida, Caterina Longo, Giuseppe Micali, Gianluca Nazzaro, Ketty Peris, Federico Venturi, Alessia Villani, Iris Zalaudek","doi":"10.5826/dpc.1503a5921","DOIUrl":"10.5826/dpc.1503a5921","url":null,"abstract":"<p><strong>Introduction: </strong>Tirbanibulin, a topical treatment for actinic keratosis (AK) with a novel antiproliferative mechanism of action, has demonstrated efficacy and a favorable tolerability profile in clinical trials and real-life studies. An insight into best-practice use of tirbanibulin in different clinical presentations of AK would be useful.</p><p><strong>Objectives: </strong>The aim of this article was to deliver advice, via expert consensus, on the optimal use of tirbanibulin in the real-life management of AK.</p><p><strong>Methods: </strong>A panel of 11 dermatologists with expertise in the treatment of AK convened to develop consensus statements about key aspects of tirbanibulin treatment in AK patients based on selected literature data and on their own clinical experience.</p><p><strong>Results: </strong>Two areas were examined and discussed: clinical assessment/diagnostic procedures and key aspects of tirbanibulin therapy. A total of 19 statements concerning clinical evaluation of AK patients, routine and advanced diagnostic instruments, patient selection, treatment modalities, and key messages for patient communication were drafted and voted on.</p><p><strong>Conclusion: </strong>Tirbanibulin should be considered as a first-line option for most patients with AK owing to its proven efficacy, good local and systemic tolerability, and a short treatment regimen of five days. All these factors encourage patient acceptability and treatment compliance. The favorable safety profile and tolerability of tirbanibulin also enable flexible therapeutic schedules, including repeated treatment cycles, if needed.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 3","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Dupilumab on Growth Parameters in Pediatric Atopic Dermatitis Patients.","authors":"Vincenzo Piccolo, Teresa Russo, Julia Nowowiejska, Giuseppe Argenziano, Carlo Mazzatenta, Andrea Bassi","doi":"10.5826/dpc.1503a5420","DOIUrl":"10.5826/dpc.1503a5420","url":null,"abstract":"","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 3","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Family and Quality of Life Challenges in Mycosis Fungoides Patients: A Case-Control Study from Shiraz, Southern Iran.","authors":"Ladan Dastgheib, Dorsa Shekouh, Mozhdeh Sepaskhah, Alireza Salehi","doi":"10.5826/dpc.1503a5361","DOIUrl":"10.5826/dpc.1503a5361","url":null,"abstract":"<p><strong>Introduction: </strong>The quality of life (QoL) of patients suffering from cutaneous malignancies like cutaneous T-cell lymphoma (CTCL) and their family caregivers is widely affected by the disease and its treatment.</p><p><strong>Objectives: </strong>This study aimed to evaluate the impact of the disease and its treatment on patients with MF and their families through self-administered questionnaires in our referral center in Shiraz.</p><p><strong>Methods: </strong>Patients with mycosis fungoides, the most common variant of CTCL, and one of their family members participated in this study by filling out the questionnaires on Dermatology Life Quality Index (DLQI) and Family Dermatology Life Quality Index (FDLQI). The World Health Organization Quality of Life Brief Version (WHOQOL-BREF) was also completed by patients and healthy controls.</p><p><strong>Results: </strong>A total of 113 cases, 91 patients' relatives, and 129 healthy controls participated in this study. The mean DLQI total score was 8.00 ± 6.41. WHOQOL-BREF and/or their subdomains were ameliorated with advanced stage, active disease, increasing MSWAT score, early disease, the head/neck location, as well as interferon and gemcitabine. \"Symptoms and feelings\" and \"leisure\" dimensions of DLQI were the most affected, while regarding WHOQOL-BREF, the disease significantly impacted the \"psychological\", \"environmental\" and \"general health\" aspects (P<0.001, P=0.045, and P<0.001, respectively). Given the sociodemographic characteristics of the study participants, patients with a higher level of education suffered more (P=0.035).The FDLQI score was 8.44 ± 6.93, not affected by sex, relationship, or caregivers' education level. Family QoL deteriorated over the course of the disease (P=0.020), head/neck lesions (P= 0.003), less than 12 months duration (P=0.029), and interferon (P=0.034).</p><p><strong>Conclusions: </strong>Due to the distress that patients and caregivers experience during the first year of diagnosis, head/neck lesions, and specific treatment, appropriate measures to prevent unrealistic expectations and better coping mechanisms are recommended.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 3","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}